2010
DOI: 10.1155/2010/729876
|View full text |Cite
|
Sign up to set email alerts
|

Combination PPARγand RXR Agonist Treatment in Melanoma Cells: Functional Importance of S100A2

Abstract: Nuclear hormone receptors, including RXR and PPARγ, represent novel therapeutic targets in melanoma. We have previously shown that the DRO subline of the amelanotic melanoma A375 responds to rexinoid and thiazolidinedione (TZD) treatment in vitro and in vivo. We performed microarray analysis of A375(DRO) after TZD and combination rexinoid/TZD treatment in which the calcium binding protein S100A2 had increased expression after rexinoid or TZD treatment and a synergistic increase to combination treatment. Increa… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
9
0
1

Year Published

2010
2010
2020
2020

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 16 publications
(11 citation statements)
references
References 25 publications
1
9
0
1
Order By: Relevance
“…1B) and the PPARγ agonist rosiglitazone (Table 4), which were combined at 0.5 μM each, up-regulated the expression of 20 genes ≥3.8-fold at 24 h in A375(DRO) melanoma cells [45]. The four most highly up-regulated genes were TIE1 (122×), S100A2 (69×), IL1B (40×), and ANGPTL4 (32×).…”
Section: Rxr Ligandsmentioning
confidence: 99%
“…1B) and the PPARγ agonist rosiglitazone (Table 4), which were combined at 0.5 μM each, up-regulated the expression of 20 genes ≥3.8-fold at 24 h in A375(DRO) melanoma cells [45]. The four most highly up-regulated genes were TIE1 (122×), S100A2 (69×), IL1B (40×), and ANGPTL4 (32×).…”
Section: Rxr Ligandsmentioning
confidence: 99%
“…The combination of rexinoids (synthetic retinoids specific for RXR) with PPAR ligands may enhance the antiproliferative effects [67], arguing for the evaluation of combination therapies. The combination of RXR agonists rexinoids and PPARγ agonists thiazolidinedione (TZD) represents novel therapeutic targets in melanoma [68]. The combination of the RXRα agonist, bexarotene, with the PPARγ agonist, rosiglitazone, has greater efficacy in growth inhibition than either single agent in colon cancer [69], suggesting a potential role for utilizing a combination regimen of an RXRα and PPARγ agonist for colon cancer.…”
Section: Modulation Of Permissive Ppar/rxr Heterodimersmentioning
confidence: 99%
“…Follicular destruction and hair cycling defects, epidermal hyperplasia [86,87] Growth and invasion arrest by NR ligands [164] AD TSLP derepression and Th2-type inflammation [88,90] Growth arrest by NR ligands [165,166,172]…”
Section: Alopeciamentioning
confidence: 99%
“…Low-calcemic VDR agonist improves allergeninduced eczema [91] Anti-proliferative and pro-differentiative properties of vitamin D analogs [184] SCC VDR polymorphisms linked to SCC development, tumor susceptibility [58,143,147] VDR polymorphisms linked to melanoma development [187][188][189] SCC VDR À/À mice susceptible to carcinogen-induced SCC through Hh pathway [149,150] BCC VDR polymorphisms linked to BCC development [146,147] BCC VDR À/À mice susceptible to carcinogen-induced BCC through Hh pathway [150] PPAR EPB formation Lamellar granules formation [43] Melanoma Growth and invasion arrest by PPAR ligands [164] PPAR agonists regulate involucrin and CD36 expression [65] Growth arrest by PPAR, RAR and RXR agonists [165,166] PPARb/d is required for EPB homeostasis [100] PPAR-mediated downregulation of b-catenin downregulates MITF [194] Activators stimulates lipid synthesis and [107] Growth arrest and induction of apoptosis by [195] (continued on next page) the malignant disease were evaluated as influences in melanoma risk, though it appeared that inactivating mutations do not appear to be a significant risk factor for the disease [192]. Recently a link was shown between a-MSH signaling and PPARc nuclear translocation that reduced proliferation rates and increased melanogenesis through the Pi(4,5)P 2 /Plcb pathway [193].…”
Section: Admentioning
confidence: 99%